Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

The 5′-AMP-Activated Protein Kinase Regulates the Function and Expression of Human Organic Anion Transporting Polypeptide 1A2

Xiaoxi Lu, Ting Chan, Zhengqi Cheng, Tahiatul Shams, Ling Zhu, Michael Murray and Fanfan Zhou
Molecular Pharmacology December 2018, 94 (6) 1412-1420; DOI: https://doi.org/10.1124/mol.118.113423
Xiaoxi Lu
School of Pharmacy (X.L., T.C., Z.C., T.S., F.Z.), Save Sight Institute (L.Z.), and Discipline of Pharmacology (M.M.), Faculty of Medicine and Health, University of Sydney, New South Wales, Australia; and Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan (T.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ting Chan
School of Pharmacy (X.L., T.C., Z.C., T.S., F.Z.), Save Sight Institute (L.Z.), and Discipline of Pharmacology (M.M.), Faculty of Medicine and Health, University of Sydney, New South Wales, Australia; and Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan (T.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhengqi Cheng
School of Pharmacy (X.L., T.C., Z.C., T.S., F.Z.), Save Sight Institute (L.Z.), and Discipline of Pharmacology (M.M.), Faculty of Medicine and Health, University of Sydney, New South Wales, Australia; and Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan (T.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tahiatul Shams
School of Pharmacy (X.L., T.C., Z.C., T.S., F.Z.), Save Sight Institute (L.Z.), and Discipline of Pharmacology (M.M.), Faculty of Medicine and Health, University of Sydney, New South Wales, Australia; and Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan (T.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ling Zhu
School of Pharmacy (X.L., T.C., Z.C., T.S., F.Z.), Save Sight Institute (L.Z.), and Discipline of Pharmacology (M.M.), Faculty of Medicine and Health, University of Sydney, New South Wales, Australia; and Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan (T.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Murray
School of Pharmacy (X.L., T.C., Z.C., T.S., F.Z.), Save Sight Institute (L.Z.), and Discipline of Pharmacology (M.M.), Faculty of Medicine and Health, University of Sydney, New South Wales, Australia; and Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan (T.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fanfan Zhou
School of Pharmacy (X.L., T.C., Z.C., T.S., F.Z.), Save Sight Institute (L.Z.), and Discipline of Pharmacology (M.M.), Faculty of Medicine and Health, University of Sydney, New South Wales, Australia; and Japanese Foundation for Cancer Research, Koto-ku, Tokyo, Japan (T.C.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

The organic anion transporting polypeptides (OATPs) are important membrane proteins that mediate the cellular uptake of drugs and endogenous substances. OATP1A2 is widely distributed in many human tissues that are targeted in drug therapy; defective OATP1A2 leads to altered drug disposition influencing therapeutic outcomes. 5′-AMP-activated protein kinase (AMPK) signaling plays an important role in the pathogenesis of the metabolic syndrome characterized by an increased incidence of type II diabetes and nonalcoholic fatty liver disease. This study investigated the regulatory role of AMPK in OATP1A2 transport function and expression. We found that the treatment of AMPK-specific inhibitor compound C (dorsomorphin dihydrochloride) decreased OATP1A2-mediated uptake of estrone-3-sulfate in a concentration- and time-dependent manner. The impaired OATP1A2 function was associated with a reduced Vmax [154.6 ± 17.9 pmol × (μg × 4 minutes)−1 in compound C–treated cells vs. 413.6 ± 52.5 pmol × (μg × 4 minutes)−1 in controls]; the Km was unchanged. The cell-surface expression of OATP1A2 was decreased by compound C treatment, but total cellular expression was unchanged. The impaired cell-surface expression of OATP1A2 was associated with accelerated internalization and impaired targeting/recycling. Silencing of the AMPK α1-subunit using specific small interfering RNA corroborated the findings with compound C and revealed a role for AMPK in regulating OATP1A2 protein stability. Overall, this study implicated AMPK in the regulation of the function and expression of OATP1A2, which potentially impacts on the disposition of OATP1A2 drug substrates that may be used to treat patients with the metabolic syndrome and other diseases.

Introduction

Solute carrier transporters (SLCs) mediate the uptake of organic ions, amino acids, nucleotides, fatty acids, and drugs into cells (Hediger et al., 2004). Within the SLC family, the SLCO subfamily, which encodes the Organic Anion Transporting Polypeptides (OATPs), is particularly important in drug disposition (Zhou et al., 2017). Of the 11 human OATP isoforms that have been identified, OATP1A2, 1B1, 1B3, and 2B1 are the best characterized and are abundantly present in the intestine, liver, kidney, and other tissues, where they facilitate drug absorption, distribution, and elimination (Kullak-Ublick et al., 1995; Kim, 2003; Steckelbroeck et al., 2004; Zhou et al., 2017).

OATPs are regulated at the transcriptional and post-translational levels. In human breast cancer cells, OATP1A2 gene transcription is activated by pregnane X receptor agonists, such as rifampin (Jigorel et al., 2006; Ma et al., 2007; Meyer zu Schwabedissen et al., 2008). The subcellular trafficking, recycling, and internalization of OATP1A2 are regulated at the post-translational level; these processes play a major role in the expression of active transporter at the cell surface. Several protein kinases regulate OATP1A2 expression at the plasma membrane. For example, protein kinase C (PKC) modulates the plasma membrane expression and function of OATP1A2, as well as OATP1B1 and OATP2B1, by regulating protein trafficking (Köck et al., 2010; Zhou et al., 2011; Hong et al., 2015). In addition, casein kinase 2 (CKII) emerged recently as an important kinase that regulates the protein subcellular trafficking of OATP1A2 (Chan et al., 2016).

The 5′-adenosine monophosphate-activated kinase (AMPK) is a cellular energy sensor in eukaryotic cells (Hardie et al., 2012). AMPK is a heterotrimeric complex that is composed of a catalytic α-subunit (either the α1 or α2 isoform), a β-subunit (either β1 or β2), and a γ-subunit (γ1, γ2, or γ3); the subunit composition of AMPK is distinct in different tissues, which is also associated with diverse kinase activity and stability (Russo et al., 2013). AMPK regulates genes, such as acetyl-CoA carboxylase and 3-hydroxy-3-methylglutaryl-CoA reductase, that mediate the biosynthesis of nutrient fatty acids and cholesterol, respectively (Beg et al., 1973; Carlson and Kim, 1973). AMPK also regulates metabolic homeostasis by activating energy production and increasing insulin sensitivity (Hardie, 2011b; Coughlan et al., 2014). AMPK dysregulation occurs in obesity, type II diabetes, and the metabolic syndrome (Steinberg and Kemp, 2009; Coughlan et al., 2013, 2014; O’Neill et al., 2013), whereas activating AMPK is the current therapeutic approach in treating such diseases (Coughlan et al., 2014). Drug transporters are known to be impaired in nonalcoholic fatty liver disease, which is a component of the metabolic syndrome, due in part to dysregulated N-glycosylation (Clarke et al., 2017). In this study, we found that OATP1A2 is regulated by AMPK, and a series of experiments were undertaken to evaluate in greater detail the regulatory role of AMPK in the function and expression of major OATP drug transporters because of its potential significance to drug therapy in patients with the metabolic syndrome.

Materials and Methods

Materials.

[3H]-Estrone-3-sulfate (E3S; specific activity 57.3 Ci/mmol) was purchased from PerkinElmer (Melbourne, VIC, Australia). Cell culture medium was obtained from Thermo Scientific (Lidcombe, NSW, Australia). Unless otherwise stated, compound C (dorsomorphin dihydrochloride) and all other chemicals and biochemicals were purchased from Sigma-Aldrich (Castle Hill, NSW, Australia).

Generation of Human Embryonic Kidney-293T Cells that Overexpress OATP Isoforms.

The C-terminal Flag (DYKDDDDK)-tagged OATP1A2-, OATP1B1-, OATP1B3-, and OATP2B1-containing plasmids were purchased or constructed in house as described previously (Zhou et al., 2011, 2013; Xu et al., 2013; Zheng et al., 2014; Shams et al., 2018). Human embryonic kidney (HEK)-293T cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum and 1% l-glutamine at 37°C in a 5% CO2 atmosphere. Cells were transfected using Lipofectamine 2000 (Thermo Scientific) following the manufacturer’s instructions. In some experiments, HEK-293T cells were transfected with AMPK α1-subunit–specific small interfering RNAs (small interfering RNAs, Cat. No. sc-29673; Bio-strategy Laboratory Products, Tingalpa, QLD, Australia) or scrambled small interfering RNAs (Cat. No. sc-37007; Bio-strategy Laboratory Products) using Lipofectamine 2000. Twenty-four hours after transfection, transporter function and protein expression were assessed.

Transport Uptake Assays.

Uptake of [3H]-E3S (300 nM; 57.3 nCi/well) by OATP1A2-, OATP1B1-, and OATP2B1-expressing cells and uptake of [3H]-cholecystokinin-8 (2 nM; 23.4 nCi/well) by OATP1B3-expressing cells were conducted at 37°C in phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 7.4) containing 5 mM glucose. Eight minutes was selected for transporter uptake assays and 4 minutes for kinetic experiments, as described previously (Johnston et al., 2014; Chan et al., 2015a; Lu et al., 2018; Shams et al., 2018). Uptake was terminated by rapidly washing cells in ice-cold PBS. Cells were then incubated with 0.2 M NaOH at room temperature for 20 minutes, followed by 0.2 M HCl for 20 minutes, before aliquots were taken for liquid scintillation counting. Control uptake rates by vector-transfected cells were subtracted from all data. In kinetic studies, the E3S concentration range was 0.05−50 μM and apparent Km and Vmax values for uptake were calculated using GraphPad Prism 5.0 (GraphPad Inc., La Jolla, CA). Data were derived in three independent experiments with triplicate repeats for each treatment.

Cell Surface Biotinylation.

The membrane-impermeable biotinylation reagent NHS-SS-biotin (Thermo Scientific) was used to determine the cell-surface expression of OATP1A2, as described before (Zhou et al., 2010, 2011, 2013; Zheng et al., 2014; Chan et al., 2016). After three washes with ice-cold PBS (pH 8.0), cells were incubated on ice with freshly prepared NHS-SS-biotin (0.5 mg/ml) for 30 minutes, then washed three times with PBS containing 100 mM glycine and twice with cold PBS. Cells were lysed with radioimmunoprecipitation assay buffer (10 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-100 containing protease inhibitor cocktail, Cat. No. R-1101; Sapphire Biosciences, Redfern, NSW, Australia). Following centrifugation at 14,000g (4°C), streptavidin-conjugated agarose beads (Thermo Scientific) were added to lysates to capture membrane-bound proteins. Proteins were eluted from beads in Laemmli buffer and subjected to SDS–polyacrylamide gel electrophoresis.

Internalization Assay.

As shown in Supplemental Fig. 1A, the internalization of biotinylated OATP1A2 was evaluated in untreated HEK-293T cells, or cells that were pretreated with compound C (10 μM, 1 hour, 37°C) (Zhou et al., 2011; Zheng et al., 2014; Chan et al., 2016). As described earlier, cells were warmed to 37°C to initiate internalization for varying times following NHS-SS-biotin prelabeling. Sodium 2-mercaptoethanesulfonate (100 mM) was then added in nick translation buffer (150 mM NaCl, 1 mM EDTA, 0.2% bovine serum albumin, 20 mM Tris, pH 8.6) to remove residual biotinylated, but noninternalized, proteins that remained at the cell surface. After washing with cold PBS (five times), cells were lysed and streptavidin-agarose beads were added to capture biotinylated proteins that had been internalized.

Targeting Assay.

We assessed the plasma membrane targeting of newly synthesized OATP1A2 protein in combination with OATP1A2 protein that had been internalized and recycled back to the plasma membrane (Supplemental Fig. 1B). OATP1A2-overexpressing HEK-293T cells were incubated in the presence and absence of compound C (10 µM, 1 hour, 37°C) (Zhou et al., 2011; Zheng et al., 2014; Chan et al., 2016) and then labeled with NHS-SS-biotin. Cells were then warmed to 37°C to initialize recycling/targeting for varying times, and an additional aliquot of NHS-SS-biotin (0.5 mg/ml, 30 minutes) was added to further label the proteins newly recycled/targeted to the cell surface. Residual NHS-SS-biotin was quenched with glycine and cells were lysed as described earlier. Following centrifugation, equivalent quantities (300 μg of protein/sample) of lysates from individual cell incubations were loaded onto streptavidin-agarose beads and subjected to electrophoresis and immunoblotting for OATP1A2. The quantity of recycled/targeted OATP1A2 at multiple time points was determined relative to initially biotinylated OATP1A2.

Recycling Assay.

HEK-293T cells that overexpressed OATP1A2 were pretreated with compound C (10 μM, 1 hour, 37°C). After an initial biotinylation, the residual NHS-SS-biotin was quenched on ice with glycine, and the cells were then warmed to 37°C for 1 minute to initialize internalization (Supplemental Fig. 1C). Sodium 2-mercaptoethanesulfonate (100 mM) in nick translation buffer was added to remove biotinylated, but noninternalized, proteins that remained at the cell surface. The cells were again warmed to 37°C to initiate recycling for varying times. At intervals, the cells were treated with sodium 2-mercaptoethanesulfonate for a second time to remove biotinylated and proteins that had been recycled to the cell surface. Cell lysates were prepared and streptavidin-agarose beads were added to isolate biotinylated proteins. The relative quantity of recycled OATP1A2 was calculated as the difference between the biotinylation signals after the first and second treatments with sodium 2-mercaptoethanesulfonate (total internalized protein and internalized, but not recycled, protein, respectively).

Electrophoresis and Immunoblotting.

Protein samples were denatured at 50°C for 30 minutes, loaded onto 7.5% polyacrylamide minigels, and electrophoresed (Bio-Rad, Gladesville, NSW, Australia). After transfer to polyvinylidene fluoride membranes in an electroelution cell (Bio-Rad), the membranes were blocked with 5% nonfat dry milk in phosphate buffered saline with Tween-20 (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, and 0.05% Tween 20, pH 7.5) for 30 minutes at room temperature. Membranes were subsequently washed with phosphate buffered saline with Tween-20 and incubated with anti-Flag primary antibody (Cat. No. 2368S, 1 µg/ml; Genesearch Pty. Ltd., Arundel, QLD, Australia) at 4°C overnight. After washing, blots were incubated with horseradish peroxidase–conjugated goat anti-rabbit IgG (Cat. No. sc-2004, 1:5000; Bio-Strategy Laboratory Products, Melbourne, VIC, Australia) for 1 hour at room temperature. Signals were then detected using the SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific). Densitometry analysis was conducted using ImageJ software (National Institutes of Health, Bethesda, MD).

Statistics.

Student’s t test was used to compare two groups of normally distributed data. Differences in transport activity with or without compound C (multiple groups) were detected by one-way analysis of variance and Dunnett’s test. Data are presented as the mean ± S.D. with a P value <0.05 considered as statistically significant.

Results

Selective Modulation of OATP1A2-Dependent Transporter Activity by AMPK Inhibition.

In initial experiments, HEK-293T cells that overexpressed OATP1A2, OATP1B1, OATP1B3, or OATP2B1 were treated with the AMPK inhibitor compound C (10 μM) for 1 hour, and then transport uptake was estimated. Compound C is the widely used, commercially available, cell-permeable AMPK-specific inhibitor with a Ki of 109 nM (Handa et al., 2011). As shown in Fig. 1A, compound C selectively impaired OATP1A2 transport activity but not that of the other three OATPs. It is known that compound C can also inhibit other signaling factors, but it has no significant inhibitory effect on kinases structurally related to AMPK (Liu et al., 2014). We pretreated the cells with AMPK activator 5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) prior to the compound C incubation (Fig. 1B). We found that AICAR can pronouncedly reverse the effect of compound C, which suggested the specific regulatory role of AMPK in OATP1A2.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Effect of AMPK inhibition on [3H]-E3S uptake by HEK-293T cells that overexpressed OATP isoforms. (A) Substrate uptake by OATP1A2, OATP1B1, OATP2B1, and OATP1B3 in overexpressing HEK-293T cells in the presence or absence of compound C (10 μM, 37°C, 60 minutes). Uptake of [3H]-E3S (300 nM) was used for OATP1A2, OATP1B1, and OATP2B1; uptake of [3H]-cholecystokinin-8 (2 nM) was used for OATP1B3, as described in the Materials and Methods. (B) AMPK activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) reverses the inhibitory effect of compound C on OATP1A2-mediated [3H]-E3S uptake. OATP1A2 overexpressing HEK-293T cells were pretreated with or without AICAR (2 mM, 37°C, 30 minutes) followed by treatment with compound C (10 μM, 37°C, 60 minutes). Uptake of [3H]-E3S (300 nM) used for OATP1A2 was measured as described in the Materials and Methods. (C) Effect of duration of treatment of OATP1A2-overexpressing HEK-293T cells with compound C (10 μM, 37°C) on [3H]-E3S uptake (300 nM). (D) Effect of compound C concentration on [3H]-E3S (300 nM) uptake by OATP1A2-overexpressing HEK-293T cells (60 minutes, 37°C). Values are the mean ± S.D. (n = 3). *P < 0.05; **P < 0.01; ***P < 0.005; different from DMSO-control. CPM, counts per minute; DMSO, dimethylsulfoxide.

In further studies, the time and concentration dependence of compound C treatment on OATP1A2 transporter function was assessed (Fig. 1, C and D). Pronounced decreases in E3S uptake were produced by 15–90 minutes of treatment with 10 µM compound C. Kinetic studies showed that AMPK inhibition decreased the Vmax for E3S uptake relative to control [154.6 ± 17.9 pmol·(μg × 4 minute)−1 vs. 413.6 ± 52.5 pmol (μg × 4 minute)−1], whereas the Km after compound C treatment was unchanged from control (44.1 ± 9.2 vs. 63.9 ± 12.9 μM; Fig. 2).

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Kinetic analysis of [3H]-E3S uptake by HEK-293T cells that overexpressed OATP1A2 in the presence or absence of compound C. [3H]-E3S concentrations ranged from 0.05 to 50 μM (4-minute uptake); cells were treated with 10 μM compound C or DMSO for 60 minutes at 37°C. Transporter kinetic parameters (Km and Vmax) were calculated using GraphPad Prism 5. Values are the mean ± S.D. (n = 3). (A) Michaelis-Menten plot. (B) Calculated Km and Vmax values of OATP1A2. **P < 0.01, different from dimethylsulfoxide (DMSO)-control.

AMPK Inhibition Impacts on the Expression of OATP1A2 at the Plasma Membrane.

The decreased Vmax of OATP1A2-mediated E3S uptake after treatment with compound C could be due to impaired transporter expression at the cell surface; this was tested directly in further studies. At the plasma membrane, OATP1A2 immunoreactive protein is present as the fully N-glycosylated mature isoform (∼95 kDa); at intracellular locations, a partially N-glycosylated immature isoform (∼60 kDa) is also present in addition to the ∼95-kDa isoform (Zhou et al., 2011, 2013; Zheng et al., 2014; Chan et al., 2016). It was found that AMPK inhibition by compound C impaired the cell-surface expression of OATP1A2 (Fig. 3, A and B) but had no effect on total OATP1A2 expression (Fig. 3, C and D).

Fig. 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 3.

Effect of AMPK inhibition on OATP1A2 protein expression. (A) Cell-surface expression of OATP1A2 with or without compound C pretreatment assessed with biotinylation assay. Overexpressing HEK-293T cells were pretreated with compound C (10 μM) or dimethylsulfoxide (DMSO) for 60 minutes at 37°C. (Top) Protein lysate probed with anti-Flag antibody. (Bottom) After stripping, the blot was reprobed with anti-Na+-K+-ATPase antibody. (B) Densitometric analysis of OATP1A2 cell-surface expression. Data were derived in three independent experiments. Values are the mean ± S.D. (n = 3). **P < 0.01, different from DMSO-control. (C) Total cellular expression of immunoreactive OATP1A2 with or without compound C pretreatment. Overexpressing HEK-293T cells were pretreated with compound C (10 μM) or DMSO for 60 minutes at 37°C. (Top) Protein lysate probed with anti-Flag antibody. (Bottom) After stripping, the blot was reprobed with anti-Na+-K+-ATPase antibody. (D) Densitometry analysis of protein total cell expression. Data were derived in three independent experiments. Values are the mean ± S.D. (n = 3). NC, vector-transfected HEK-293T cells.

AMPK Regulates Subcellular Trafficking of OATP1A2.

Previous studies have shown that OATP1A2 is trafficked continuously between the cell surface and intracellular compartments (Zhou et al., 2011; Zheng et al., 2014; Chan et al., 2016). Trafficking processes include internalization from the cell surface to intracellular compartments, recycling from intracellular compartments back to the cell surface, and targeting of newly synthesized protein to the cell surface. We conducted biotinylation-based assays to investigate the effect of AMPK inhibition on OATP1A2 trafficking, in particular internalization, recycling, and targeting.

As shown in Fig. 4A, AMPK inhibition accelerated the internalization of OATP1A2 from the cell surface to intracellular compartments. In addition, the rate at which OATP1A2 protein was trafficked from intracellular compartments back to the cell surface and the recycling of OATP1A2 were impaired by AMPK inhibition (Fig. 4, B and C).

Fig. 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 4.

Protein trafficking of OATP1A2 in the overexpressing HEK-293T cells with or without compound C treatment. (A) OATP1A2 internalization process. (Left) OATP1A2 internalization assay was conducted as described in the Materials and Methods. Cells were pretreated with compound C or dimethylsulfoxide (DMSO; 10 μM, 60 minutes, 37°C). Cells were allowed to internalize for 0.5, 1.5, and 3 minutes at 37°C. (Right) Densitometric analysis of the internalized transporter protein as a percentage of the total initially biotinylated OATP1A2 at the cell surface. (B) OATP1A2 membrane-targeting process. (Left) OATP1A2 targeting was evaluated as described in the Materials and Methods. Cells were pretreated with compound C or DMSO (10 μM, 60 minutes, 37°C). Additional biotin labeling was allowed for 5, 10, and 15 minutes at 37°C. (Right) Densitometric analysis of transporter protein that was newly targeted to the cell surface (newly synthesized and previously internalized protein combined) as a percentage of the total initially biotinylated OATP1A2 at the cell surface. (C) OATP1A2 recycling process. (Left) OATP1A2 recycling was assessed as described in the Materials and Methods. Cells were pretreated with compound C or DMSO (10 μM, 60 minutes, 37°C). Cells were allowed to internalize for 1 minute at 37°C, and after the first stripping step, cells were allowed to internalize for 1, 2, or 3 minutes at 37°C. (Right) Densitometric analysis of recycled transporter protein as a percentage of the total initially biotinylated OATP1A2 at the cell surface before initiation of recycling (the protein signal at t = 0 minutes was subtracted from each time point). A representative blot is presented; each experiment was repeated on three occasions. Values are the mean ± S.D. (n = 3). **P < 0.01, different from DMSO-control. NC, vector-transfected HEK-293T cells; SC, stripping control.

AMPK Silencing Modulates OATP1A2 Activity and Expression.

As mentioned, heterotrimeric AMPK consists of a catalytic α-subunit and regulatory β- and γ-subunits (Mihaylova and Shaw, 2011). We also adopted an independent approach from chemical inhibition to verify the specific regulatory role of AMPK on OATP1A2. Knockdown of the AMPK α-subunit has been shown to disrupt AMPK signaling in HEK-293T cells (Tzatsos and Tsichlis, 2007; Tangeman et al., 2012). In the present study, we used small interfering RNA silencing of the AMPK α1-subunit to corroborate and extend the findings with compound C on OATP1A2 regulation. Following AMPK α1 silencing, E3S uptake was decreased in HEK-293T cells to ∼6.1% of control scrambled small interfering RNA-transfected cells (P < 0.001, Fig. 5B). Similar to compound C treatment, such AMPK α1 silencing decreased the expression of OATP1A2 at the plasma membrane (Fig. 5, C and D). Such observation was also validated with another independent small interfering RNA obtained from Thermo Scientific (Supplemental Fig. 2). However, unlike AMPK inhibition, AMPK α1 silencing also appeared to decrease protein stability (Fig. 5, C and D). The additional effect of small interfering RNA silencing on OATP1A2 protein stability is possibly due to the long-term effect of AMPK inhibition (48 hours after cotransfection of OATP1A2 and AMPK α1 small interfering RNA) as compared with the acute effect induced by compound C (60-minute treatment).

Fig. 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 5.

The effect of AMPK α1-subunit silencing on the uptake function and protein expression of OATP1A2. (A) Total cellular expression of AMPK α1-subunit in HEK-293T cells that overexpressed OATP1A2 after transfection with an AMPK α1–specific or scrambled small interfering RNAs. (Top) Immunoblot was probed with anti-AMPK α1 antibody. (Bottom) After stripping, the blot was reprobed with anti–β-actin antibody. (B) [3H]-E3S uptake was performed in HEK-293T cells that overexpressed OATP1A2 and were transfected with either AMPK α1–specific or scrambled small interfering RNAs. ***P < 0.005, different from scrambled small interfering RNA transfected control. (C) Total cellular and plasma membrane expression of OATP1A2 in HEK-293T cells that overexpressed OATP1A2 and were transfected with either AMPK α1–specific or scrambled small interfering RNAs. (Top) OATP1A2 cell-surface expression evaluated via biotinylation analysis. (Middle) Total cellular expression of OATP1A2 assessed by immunoblotting. (Bottom) After stripping, the blot from the middle panel was reprobed with an anti–β-actin antibody. (D) Densitometric analysis of OATP1A2 cell-surface and total cell expression. Data were derived in three independent experiments. Values are the mean ± S.D. (n = 3). *P < 0.05; **P < 0.01; different from scrambled small interfering RNA transfected control. (E) Stability of OATP1A2 protein with or without AMPK silencing. HEK-293T cells that overexpressed OATP1A2 were transfected with either AMPK α1–specific or scrambled small interfering RNAs and were treated with the protein synthesis inhibitor cycloheximide (100 μg/ml) for varying times as shown. Immunoblotting analysis was conducted to analyze expression of OATP1A2. (Top) Total cellular expression of OATP1A2 after cycloheximide treatment. (Middle) After stripping, the blot was reprobed with anti–β-actin antibody. (Bottom) Densitometric analysis of the ratio of OATP1A2 to β-actin as a percentage of that at the 8-hour time point. A representative blot is presented; each experiment was repeated on three occasions. Values are the mean ± S.D. (n = 3). **P < 0.01, different from scrambled small interfering RNA transfected control. NC, vector-transfected HEK-293T cells.

We further treated HEK-293T cells with cycloheximide (100 μg/ml) in a time-course experiment to inhibit protein synthesis. As shown in Fig. 5E, AMPK α1 silencing impaired OATP1A2 stability by accelerating the degradation of the transporter protein.

Discussion

OATP1A2 is abundantly located in the epithelium of many tissues and influences the disposition of numerous drugs, xenobiotics, and endobiotics (Kullak-Ublick et al., 1995; Steckelbroeck et al., 2004; Liu and Li, 2014). At the apical membrane of renal tubular cells, OATP1A2 mediates the reabsorption of xenobiotics (Lee et al., 2005); in the biliary epithelium, OATP1A2 facilitates the excretion of xenobiotics into bile; and at the luminal membrane of the blood-brain barrier, OATP1A2 modulates the uptake of opioid analgesic peptides and other central nervous system–active agents into the brain (Liu et al., 2015). More recently, OATP1A2 has been detected on the apical membrane of the retinal pigment epithelium, where it facilitates the uptake of retinoids (Chan et al., 2015b; Gao et al., 2015). Therefore, OATP1A2 dysfunction may impair drug pharmacokinetics and disposition that could influence the outcomes of drug therapy and may also impair endobiotic uptake into target tissues.

AMPK is an established regulator of metabolic homeostasis because it modulates the expression and function of proteins that control energy production and utilization (Ronnebaum et al., 2014). There is evidence that AMPK regulates epithelial ion transporters of physiologic importance. For instance, AMPK phosphorylates the renal-specific Na+-K+-2Cl−-cotransporter (SLC12A1) and the cystic fibrosis transmembrane conductance regulator (ABCC7), as well as the proximal tubule vacuolar H+-ATPase (Hallows et al., 2003; Fraser et al., 2007; Al-bataineh et al., 2014). Through two independent approaches (chemical inhibition and small interfering RNA knockdown), the present findings now indicate that the SLC transporter OATP1A2, which is important in drug disposition, is also potentially regulated by AMPK signaling. Dysregulation was selective for OATP1A2 because the activity of three other major drug-transporting OATPs was unchanged by treatment of cells with the AMPK inhibitor compound C (Fig. 1A). This also indicated that the regulatory effect of AMPK on OATP1A2 is not likely due to the changes in cellular energy hemostasis.

Kinetic analysis indicated that the maximal rate of E3S uptake by OATP1A2 was decreased by AMPK inhibition, whereas the apparent affinity of the transporter for E3S was unchanged (Fig. 2). Expression of OATP1A2 at the plasma membrane, but not its total cellular expression, was decreased by compound C treatment, which is consistent with altered trafficking of the transporter (Fig. 3). Using a series of trafficking protocols, we found that AMPK inhibition and silencing increased the internalization and decreased the recycling of OATP1A2 (Fig. 4). In addition to the decrease in OATP1A2 transport function and cell-surface expression, the stability of the transporter protein was also impaired by AMPK α1 silencing (Fig. 5). Taken together, the present findings indicate that AMPK signaling plays an important role in regulating the internalization, targeting, recycling, and stability of OATP1A2. We also tested the potential significance of the present findings in ex vivo and in vivo settings. As we reported before, OATP1A2 is known to express in human retinal pigmented epithelial cells (Chan et al., 2015b; Xu et al., 2016); therefore, we evaluated the response of OATP1A2 to AMPK inhibition in human primary retinal pigmented epithelial cells (Supplemental Fig. 3A). Consistently, OATP1A2-mediated [3H]-E3S uptake was statistically significantly reduced upon compound C pretreatment (P < 0.05), which suggested that OATP1A2 response to AMPK inhibition is not restricted in renal cells. Although there are no direct rodent orthologs of human OATP1A2, mouse Oatp1 (Oatp1a1) has ∼70% similarity to OATP1A2 at the amino acid level. We found that the transport function in HEK-293T cells that overexpressed mouse Oatp1 was decreased by treatment with the AMPK inhibitor compound C. Further, the expression of immunoreactive Oatp1 protein was decreased in the liver of male AMPK β1–null mice (Dzamko et al., 2010; Mount et al., 2012) (Supplemental Fig. 3). AMPK dysregulation has been widely indicated in obesity, diabetes, and the metabolic syndrome (Steinberg and Kemp, 2009; Coughlan et al., 2014), and decreased mouse Oatp1 expression was reported in diabetic rodent models by us and others (Xu et al., 2015; Li et al., 2017), so our study is clinically relevant to elucidate the altered drug response in these diseases. Moreover, we acknowledge that under the physiologic condition, the regulatory machinery of AMPK may react differently from that observed in the overexpressing in vitro system, so future studies may verify our findings in in vivo models.

The consensus AMPK phosphorylation motif spans ∼11 amino acid residues and consists of a central Ser/Thr/Tyr residue with one or more basic residues (Arg/Lys/His) at the N-terminal end and one or more hydrophobic residues (e.g., Leu/Met/Ile/Val/Phe) (Hardie, 2011a). Inspection of the primary amino acid sequence of OATP1A2 identified Ser-36 and Ser-313 as potential AMPK phosphorylation sites; the other three drug-transporting OATP isoforms that were evaluated in the present study lacked analogous serine residues (Supplemental Fig. 4A). We tested the functional roles of Ser-36 and Ser-313 using site-directed mutagenesis. However, E3S uptake by the mutagenized OATP1A2 transporters was unchanged from wild type, which suggests either that AMPK does not mediate OATP1A2 phosphorylation directly or that atypical AMPK regulatory sites might be involved (Supplemental Fig. 4B). As for the previous reports, the protein trafficking of OATPs is also facilitated by other chaperon proteins, such as PDZ-domain containing proteins (Zheng et al., 2014; Murray and Zhou, 2017; Ferreira et al., 2018); therefore, it is plausible that AMPK inhibition impacts on chaperon proteins and indirectly influences the expression and function of OATP1A2. Further studies to explore the impact of AMPK inhibition on these chaperon proteins and the potential atypical AMPK motifs in OATP1A2 are now warranted.

The interplay between multiple kinases modulates the dynamic trafficking of a number of transport proteins. The internalization of glucose transporter 4 (GLUT4; SLC2A4) was impaired and its expression at the plasma membrane of skeletal muscle cells was increased by activation of AMPK and PKC (Antonescu et al., 2008; Klip et al., 2009). In contrast, expression of the creatine transporter (SLC6A8) was decreased by AMPK and PKC activation (Li et al., 2010), and we found previously that OATP1A2 trafficking was regulated by PKC and CKII (Fig. 6) (Zhou et al., 2011; Chan et al., 2016; Murray and Zhou, 2017). Similar to AMPK inhibition, PKC activation accelerated the internalization of OATP1A2. Although PKC activation did not influence OATP1A2 recycling/targeting, AMPK inhibition also decreased the recycling and membrane targeting of the transporter. Thus, it is feasible that the regulatory actions of PKC on OATP1A2 could be related in part to AMPK signaling. Similarities between AMPK and CKII inhibition were noted because both decreased OATP1A2 recycling and targeting (Fig. 6) (Chan et al., 2016). However, unlike AMPK inhibition, CKII inhibition impaired the internalization of OATP1A2. Overall, the regulatory effects of CK2 and PKC only partially overlapped with that of AMPK. Thus, OATP1A2 protein trafficking is subject to complex regulations by a group of kinases including AMPK, PKC, and CKII, but AMPK was unlikely the “master” regulatory signaling upstream of PKC or CK2. The main focus of our current study was to explore how OATP1A2 was regulated by AMPK, which influences drug performance in disease treatments; therefore, detailed AMPK signaling pathway mapping involved in this regulation or exploration of the potential atypical AMPK motifs involved in such regulation is beyond the scope of this study and has less relevance to drug treatments, which will be included in our future studies.

Fig. 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 6.

Multiple signaling kinases regulate the membrane targeting, internalization, recycling, and degradation of OATP1A2. CIS, cisternae; ER, endoplasmic reticulum.

In summary, the present study is the first to demonstrate a regulatory role for AMPK on human drug-transporting OATPs. AMPK regulated the expression and function of OATP1A2 by modulating its subcellular trafficking and stability. The dysregulation of AMPK has been associated with obesity, type II diabetes, and other manifestations of the metabolic syndrome, such as nonalcoholic fatty liver disease. Indeed, the present findings are compatible with those of Clarke et al. (2017), who reported that transporter N-glycosylation and trafficking were impaired in nonalcoholic fatty liver disease. Drug therapy may be complicated in patients with obesity or the metabolic syndrome. For example, obesity is associated with a higher incidence of chronic myelogenous leukemia, for which the OATP1A2 substrate imatinib is a front-line treatment (Strom et al., 2009). The present information provides the basis for future studies on how OATP transport activity is regulated in disease. This information could be taken into consideration in drug selection for optimal therapy in patients with the metabolic syndrome.

Acknowledgments

We thank Bruce E. Kemp from the Department of Medicine, University of Melbourne, Australia, for generously providing the AMPK β1-subunit knockout mice samples.

Authorship Contributions

Participated in research design: Lu, Zhou.

Conducted experiments: Lu, Chan, Cheng, Shams, Zhou.

Contributed new reagents or analytic tools: Murray.

Performed data analysis: Lu, Zhu, Murray, Zhou.

Wrote or contributed to the writing of the manuscript: Lu, Zhu, Murray, Zhou.

Footnotes

    • Received June 20, 2018.
    • Accepted September 28, 2018.
  • This work was supported by the National Health and Medical Research Council of Australia [Grant APP1025101].

  • The authors state no conflict of interest.

  • https://doi.org/10.1124/mol.118.113423.

  • ↵Embedded ImageThis article has supplemental material available at molpharm.aspetjournals.org.

Abbreviations

AICIR, 5-Aminoimidazole-4-carboxamide ribonucleotide; AMPK
5′-AMP-activated protein kinase
CKII
casein kinase 2
compound C
dorsomorphin dihydrochloride
E3S
estrone-3-sulfate
HEK
human embryonic kidney
OATP
organic anion transporting polypeptide
PBS
phosphate-buffered saline
PKC
protein kinase C
SLC
solute carrier transporter
  • Copyright © 2018 by The American Society for Pharmacology and Experimental Therapeutics

References

  1. ↵
    1. Al-bataineh MM,
    2. Gong F,
    3. Marciszyn AL,
    4. Myerburg MM, and
    5. Pastor-Soler NM
    (2014) Regulation of proximal tubule vacuolar H(+)-ATPase by PKA and AMP-activated protein kinase. Am J Physiol Renal Physiol 306:F981–F995.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Antonescu CN,
    2. Díaz M,
    3. Femia G,
    4. Planas JV, and
    5. Klip A
    (2008) Clathrin-dependent and independent endocytosis of glucose transporter 4 (GLUT4) in myoblasts: regulation by mitochondrial uncoupling. Traffic 9:1173–1190.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Beg ZH,
    2. Allmann DW, and
    3. Gibson DM
    (1973) Modulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity with cAMP and wth protein fractions of rat liver cytosol. Biochem Biophys Res Commun 54:1362–1369.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Carlson CA and
    2. Kim KH
    (1973) Regulation of hepatic acetyl coenzyme A carboxylase by phosphorylation and dephosphorylation. J Biol Chem 248:378–380.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Chan T,
    2. Cheung FS,
    3. Zheng J,
    4. Lu X,
    5. Zhu L,
    6. Grewal T,
    7. Murray M, and
    8. Zhou F
    (2016) Casein kinase 2 is a novel regulator of the human organic anion transporting polypeptide 1A2 (OATP1A2) trafficking. Mol Pharm 13:144–154.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Chan T,
    2. Zheng J,
    3. Zhu L,
    4. Grewal T,
    5. Murray M, and
    6. Zhou F
    (2015a) Putative transmembrane domain 6 of the human organic anion transporting polypeptide 1A2 (OATP1A2) influences transporter substrate binding, protein trafficking, and quality control. Mol Pharm 12:111–119.
    OpenUrlCrossRef
  7. ↵
    1. Chan T,
    2. Zhu L,
    3. Madigan MC,
    4. Wang K,
    5. Shen W,
    6. Gillies MC, and
    7. Zhou F
    (2015b) Human organic anion transporting polypeptide 1A2 (OATP1A2) mediates cellular uptake of all-trans-retinol in human retinal pigmented epithelial cells. Br J Pharmacol 172:2343–2353.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Clarke JD,
    2. Novak P,
    3. Lake AD,
    4. Hardwick RN, and
    5. Cherrington NJ
    (2017) Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease. Liver Int 37:1074–1081.
    OpenUrl
  9. ↵
    1. Coughlan KA,
    2. Valentine RJ,
    3. Ruderman NB, and
    4. Saha AK
    (2013) Nutrient excess in AMPK downregulation and insulin resistance. J Endocrinol Diabetes Obes 1:1008.
    OpenUrlPubMed
  10. ↵
    1. Coughlan KA,
    2. Valentine RJ,
    3. Ruderman NB, and
    4. Saha AK
    (2014) AMPK activation: a therapeutic target for type 2 diabetes? Diabetes Metab Syndr Obes 7:241–253.
    OpenUrlPubMed
  11. ↵
    1. Dzamko N,
    2. van Denderen BJ,
    3. Hevener AL,
    4. Jørgensen SB,
    5. Honeyman J,
    6. Galic S,
    7. Chen ZP,
    8. Watt MJ,
    9. Campbell DJ,
    10. Steinberg GR, et al.
    (2010) AMPK beta1 deletion reduces appetite, preventing obesity and hepatic insulin resistance. J Biol Chem 285:115–122.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Ferreira C,
    2. Hagen P,
    3. Stern M,
    4. Hussner J,
    5. Zimmermann U,
    6. Grube M, and
    7. Meyer Zu Schwabedissen HE
    (2018) The scaffold protein PDZK1 modulates expression and function of the organic anion transporting polypeptide 2B1. Eur J Pharm Sci 120:181–190.
    OpenUrl
  13. ↵
    1. Fraser SA,
    2. Gimenez I,
    3. Cook N,
    4. Jennings I,
    5. Katerelos M,
    6. Katsis F,
    7. Levidiotis V,
    8. Kemp BE, and
    9. Power DA
    (2007) Regulation of the renal-specific Na+-K+-2Cl- co-transporter NKCC2 by AMP-activated protein kinase (AMPK). Biochem J 405:85–93.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Gao B,
    2. Vavricka SR,
    3. Meier PJ, and
    4. Stieger B
    (2015) Differential cellular expression of organic anion transporting peptides OATP1A2 and OATP2B1 in the human retina and brain: implications for carrier-mediated transport of neuropeptides and neurosteriods in the CNS. Pflugers Arch 467:1481–1493.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Hallows KR,
    2. McCane JE,
    3. Kemp BE,
    4. Witters LA, and
    5. Foskett JK
    (2003) Regulation of channel gating by AMP-activated protein kinase modulates cystic fibrosis transmembrane conductance regulator activity in lung submucosal cells. J Biol Chem 278:998–1004.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Handa N,
    2. Takagi T,
    3. Saijo S,
    4. Kishishita S,
    5. Takaya D,
    6. Toyama M,
    7. Terada T,
    8. Shirouzu M,
    9. Suzuki A,
    10. Lee S, et al.
    (2011) Structural basis for compound C inhibition of the human AMP-activated protein kinase α2 subunit kinase domain. Acta Crystallogr D Biol Crystallogr 67:480–487.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Hardie DG
    (2011a) AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 25:1895–1908.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Hardie DG
    (2011b) Sensing of energy and nutrients by AMP-activated protein kinase. Am J Clin Nutr 93:891S–896S.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Hardie DG,
    2. Ross FA, and
    3. Hawley SA
    (2012) AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol 13:251–262.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Hediger MA,
    2. Romero MF,
    3. Peng JB,
    4. Rolfs A,
    5. Takanaga H, and
    6. Bruford EA
    (2004) The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteinsIntroduction. Pflugers Arch 447:465–468.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Hong M,
    2. Hong W,
    3. Ni C,
    4. Huang J, and
    5. Zhou C
    (2015) Protein kinase C affects the internalization and recycling of organic anion transporting polypeptide 1B1. Biochim Biophys Acta 1848 (10 Pt A):2022–2030.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Jigorel E,
    2. Le Vee M,
    3. Boursier-Neyret C,
    4. Parmentier Y, and
    5. Fardel O
    (2006) Differential regulation of sinusoidal and canalicular hepatic drug transporter expression by xenobiotics activating drug-sensing receptors in primary human hepatocytes. Drug Metab Dispos 34:1756–1763.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Johnston RA,
    2. Rawling T,
    3. Chan T,
    4. Zhou F, and
    5. Murray M
    (2014) Selective inhibition of human solute carrier transporters by multikinase inhibitors. Drug Metab Dispos 42:1851–1857.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Kim RB
    (2003) Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 33 (Suppl 2):1–5.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Klip A,
    2. Schertzer JD,
    3. Bilan PJ,
    4. Thong F, and
    5. Antonescu C
    (2009) Regulation of glucose transporter 4 traffic by energy deprivation from mitochondrial compromise. Acta Physiol (Oxf) 196:27–35.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Köck K,
    2. Koenen A,
    3. Giese B,
    4. Fraunholz M,
    5. May K,
    6. Siegmund W,
    7. Hammer E,
    8. Völker U,
    9. Jedlitschky G,
    10. Kroemer HK, et al.
    (2010) Rapid modulation of the organic anion transporting polypeptide 2B1 (OATP2B1, SLCO2B1) function by protein kinase C-mediated internalization. J Biol Chem 285:11336–11347.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Kullak-Ublick GA,
    2. Hagenbuch B,
    3. Stieger B,
    4. Schteingart CD,
    5. Hofmann AF,
    6. Wolkoff AW, and
    7. Meier PJ
    (1995) Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 109:1274–1282.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Lee W,
    2. Glaeser H,
    3. Smith LH,
    4. Roberts RL,
    5. Moeckel GW,
    6. Gervasini G,
    7. Leake BF, and
    8. Kim RB
    (2005) Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem 280:9610–9617.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Li F,
    2. Ling ZL,
    3. Wang ZJ,
    4. Zhong ZY,
    5. Shu N,
    6. Zhang M,
    7. Liu C,
    8. Liu L, and
    9. Liu XD
    (2017) Differential effects of pravastatin on the pharmacokinetics of paroxetine in normal and diabetic rats. Xenobiotica 47:20–30.
    OpenUrl
  30. ↵
    1. Li H,
    2. Thali RF,
    3. Smolak C,
    4. Gong F,
    5. Alzamora R,
    6. Wallimann T,
    7. Scholz R,
    8. Pastor-Soler NM,
    9. Neumann D, and
    10. Hallows KR
    (2010) Regulation of the creatine transporter by AMP-activated protein kinase in kidney epithelial cells. Am J Physiol Renal Physiol 299:F167–F177.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Liu H,
    2. Yu N,
    3. Lu S,
    4. Ito S,
    5. Zhang X,
    6. Prasad B,
    7. He E,
    8. Lu X,
    9. Li Y,
    10. Wang F, et al.
    (2015) Solute carrier family of the organic anion-transporting polypeptides 1A2- Madin-Darby canine kidney II: a promising in vitro system to understand the role of organic anion-transporting polypeptide 1A2 in blood-brain barrier drug penetration. Drug Metab Dispos 43:1008–1018.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Liu T and
    2. Li Q
    (2014) Organic anion-transporting polypeptides: a novel approach for cancer therapy. J Drug Target 22:14–22.
    OpenUrl
  33. ↵
    1. Liu X,
    2. Chhipa RR,
    3. Nakano I, and
    4. Dasgupta B
    (2014) The AMPK inhibitor compound C is a potent AMPK-independent antiglioma agent. Mol Cancer Ther 13:596–605.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Lu X,
    2. Chan T,
    3. Zhu L,
    4. Bao X,
    5. Velkov T,
    6. Zhou QT,
    7. Li J,
    8. Chan HK, and
    9. Zhou F
    (2018) The inhibitory effects of eighteen front-line antibiotics on the substrate uptake mediated by human organic anion/cation transporters, organic anion transporting polypeptides and oligopeptide transporters in in vitro models. Eur J Pharm Sci 115:132–143.
    OpenUrl
  35. ↵
    1. Ma X,
    2. Shah YM,
    3. Guo GL,
    4. Wang T,
    5. Krausz KW,
    6. Idle JR, and
    7. Gonzalez FJ
    (2007) Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther 322:391–398.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Meyer zu Schwabedissen HE,
    2. Tirona RG,
    3. Yip CS,
    4. Ho RH, and
    5. Kim RB
    (2008) Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res 68:9338–9347.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Mihaylova MM and
    2. Shaw RJ
    (2011) The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 13:1016–1023.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Mount PF,
    2. Gleich K,
    3. Tam S,
    4. Fraser SA,
    5. Choy SW,
    6. Dwyer KM,
    7. Lu B,
    8. Denderen BV,
    9. Fingerle-Rowson G,
    10. Bucala R, et al.
    (2012) The outcome of renal ischemia-reperfusion injury is unchanged in AMPK-β1 deficient mice. PLoS One 7:e29887.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Murray M and
    2. Zhou F
    (2017) Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease. Br J Pharmacol 174:1908–1924.
    OpenUrlCrossRefPubMed
  40. ↵
    1. O’Neill HM,
    2. Holloway GP, and
    3. Steinberg GR
    (2013) AMPK regulation of fatty acid metabolism and mitochondrial biogenesis: implications for obesity. Mol Cell Endocrinol 366:135–151.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Ronnebaum SM,
    2. Patterson C, and
    3. Schisler JC
    (2014) Minireview: hey U(PS): metabolic and proteolytic homeostasis linked via AMPK and the ubiquitin proteasome system. Mol Endocrinol 28:1602–1615.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Russo GL,
    2. Russo M, and
    3. Ungaro P
    (2013) AMP-activated protein kinase: a target for old drugs against diabetes and cancer. Biochem Pharmacol 86:339–350.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Shams T,
    2. Lu X,
    3. Zhu L, and
    4. Zhou F
    (2018) The inhibitory effects of five alkaloids on the substrate transport mediated through human organic anion and cation transporters. Xenobiotica 48:197–205.
    OpenUrl
  44. ↵
    1. Steckelbroeck S,
    2. Nassen A,
    3. Ugele B,
    4. Ludwig M,
    5. Watzka M,
    6. Reissinger A,
    7. Clusmann H,
    8. Lütjohann D,
    9. Siekmann L,
    10. Klingmüller D, et al.
    (2004) Steroid sulfatase (STS) expression in the human temporal lobe: enzyme activity, mRNA expression and immunohistochemistry study. J Neurochem 89:403–417.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Steinberg GR and
    2. Kemp BE
    (2009) AMPK in health and disease. Physiol Rev 89:1025–1078.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Strom SS,
    2. Yamamura Y,
    3. Kantarijian HM, and
    4. Cortes-Franco JE
    (2009) Obesity, weight gain, and risk of chronic myeloid leukemia. Cancer Epidemiol Biomarkers Prev 18:1501–1506.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Tangeman L,
    2. Wyatt CN, and
    3. Brown TL
    (2012) Knockdown of AMP-activated protein kinase alpha 1 and alpha 2 catalytic subunits. J RNAi Gene Silencing 8:470–478.
    OpenUrlPubMed
  48. ↵
    1. Tzatsos A and
    2. Tsichlis PN
    (2007) Energy depletion inhibits phosphatidylinositol 3-kinase/Akt signaling and induces apoptosis via AMP-activated protein kinase-dependent phosphorylation of IRS-1 at Ser-794. J Biol Chem 282:18069–18082.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Xu C,
    2. Zhu L,
    3. Chan T,
    4. Lu X,
    5. Shen W,
    6. Gillies MC, and
    7. Zhou F
    (2015) The altered renal and hepatic expression of solute carrier transporters (SLCs) in type 1 diabetic mice. PLoS One 10:e0120760.
    OpenUrl
  50. ↵
    1. Xu C,
    2. Zhu L,
    3. Chan T,
    4. Lu X,
    5. Shen W,
    6. Madigan MC,
    7. Gillies MC, and
    8. Zhou F
    (2016) Chloroquine and hydroxychloroquine are novel inhibitors of human organic anion transporting polypeptide 1A2. J Pharm Sci 105:884–890.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Xu F,
    2. Li Z,
    3. Zheng J,
    4. Gee Cheung FS,
    5. Chan T,
    6. Zhu L,
    7. Zhuge H, and
    8. Zhou F
    (2013) The inhibitory effects of the bioactive components isolated from Scutellaria baicalensis on the cellular uptake mediated by the essential solute carrier transporters. J Pharm Sci 102:4205–4211.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Zheng J,
    2. Chan T,
    3. Cheung FS,
    4. Zhu L,
    5. Murray M, and
    6. Zhou F
    (2014) PDZK1 and NHERF1 regulate the function of human organic anion transporting polypeptide 1A2 (OATP1A2) by modulating its subcellular trafficking and stability. PLoS One 9:e94712.
    OpenUrlCrossRefPubMed
  53. ↵
    1. Zhou F,
    2. Lee AC,
    3. Krafczyk K,
    4. Zhu L, and
    5. Murray M
    (2011) Protein kinase C regulates the internalization and function of the human organic anion transporting polypeptide 1A2. Br J Pharmacol 162:1380–1388.
    OpenUrlCrossRefPubMed
  54. ↵
    1. Zhou F,
    2. Zheng J,
    3. Zhu L,
    4. Jodal A,
    5. Cui PH,
    6. Wong M,
    7. Gurney H,
    8. Church WB, and
    9. Murray M
    (2013) Functional analysis of novel polymorphisms in the human SLCO1A2 gene that encodes the transporter OATP1A2. AAPS J 15:1099–1108.
    OpenUrlCrossRefPubMed
  55. ↵
    1. Zhou F,
    2. Zhu L,
    3. Cui PH,
    4. Church WB, and
    5. Murray M
    (2010) Functional characterization of nonsynonymous single nucleotide polymorphisms in the human organic anion transporter 4 (hOAT4). Br J Pharmacol 159:419–427.
    OpenUrlCrossRefPubMed
  56. ↵
    1. Zhou F,
    2. Zhu L,
    3. Wang K, and
    4. Murray M
    (2017) Recent advance in the pharmacogenomics of human solute carrier transporters (SLCs) in drug disposition. Adv Drug Deliv Rev 116:21–36.
    OpenUrl
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 94 (6)
Molecular Pharmacology
Vol. 94, Issue 6
1 Dec 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The 5′-AMP-Activated Protein Kinase Regulates the Function and Expression of Human Organic Anion Transporting Polypeptide 1A2
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

AMPK Signaling Regulates the Function/Expression of OATP1A2

Xiaoxi Lu, Ting Chan, Zhengqi Cheng, Tahiatul Shams, Ling Zhu, Michael Murray and Fanfan Zhou
Molecular Pharmacology December 1, 2018, 94 (6) 1412-1420; DOI: https://doi.org/10.1124/mol.118.113423

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

AMPK Signaling Regulates the Function/Expression of OATP1A2

Xiaoxi Lu, Ting Chan, Zhengqi Cheng, Tahiatul Shams, Ling Zhu, Michael Murray and Fanfan Zhou
Molecular Pharmacology December 1, 2018, 94 (6) 1412-1420; DOI: https://doi.org/10.1124/mol.118.113423
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Analgesic Effects and Mechanisms of Licochalcones
  • Induced Fit Ligand Binding to CYP3A4
  • Englerin A Inhibits T-Type Channels
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics